KMO Inhibitor

Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC₅₀ of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations.

TES-1025 is a potent and selective human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) inhibitor with an IC₅₀ of 13 nM.

GSK180 is a selective, competitive, and potent inhibitor of kynurenine-3-monooxygenase (KMO), a key enzyme of tryptophan metabolism (IC₅₀, ~6 nM), but shows negligible activity against other enzymes on the tryptophan pathway. GSK180 rapidly changes levels of kynurenine pathway metabolites, and acts as a useful tool to probe the therapeutic potential of KMO inhibition.

Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ_1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC₅₀ = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line.

GSK 366 is a type II kynurenine-3-monooxygenase (KMO) inhibitor with IC₅₀ values of 2.3 nM and 0.7 nM for human KMO and P. fluorescens-KMO (Pf-KMO). GSK 366 binds to KMO’s substrate site, prevents productive NADPH association, substrate binding, and FAD hydroperoxy species formation. GSK 366 does not stimulate hydrogen peroxide (H₂O₂) production and reduces H₂O₂ levels. GSK 366 can be used for the researches of inflammation and neurological disease, such as acute pancreatitis multiple organ dysfunction syndrome and Alzheimer’s disease.

KMO-IN-1 is a KMO inhibitor with a mean pIC₅₀ of 8.5 against KMO. KMO-IN-1 can be used in the research of acute pancreatitis.

CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease.

Cannflavin A (Standard) is the analytical standard of Cannflavin A. This product is intended for research and analytical applications. Cannflavin A can be isolated from Cannabis sativa L.. Cannflavin A has anti-cancer, neuroprotective and anti-inflammatory activity. Cannflavin A inhibits Aβ_1-42 aggregation. Cannflavin A also inhibits kynurenine-3-monooxygenase (KMO) (IC₅₀ = 29.4 μM). Cannflavin A activates apoptosis via caspase-3 cleavage. Cannflavin A exerts anti-inflammatory effects by inhibiting pro-inflammatory enzymes, including prostaglandin E2 and cytochrome c oxidases I and II in PC12 cell line.

JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC₅₀ of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research.

Ro 61-8048 (Standard) is the analytical standard of Ro 61-8048. This product is intended for research and analytical applications. Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations.